Beta-2 adrenergic agonist (botanical)

Plain-language summaryIntrigue 38 / 100

Higenamine is a benzylisoquinoline alkaloid found in lotus, aconite, and several traditional Chinese medicine herbs. It acts as a beta-2-preferring adrenergic agonist (with weaker beta-1 activity), giving it a pharmacological profile loosely similar to clenbuterol but at much lower potency. Marketed in pre-workout supplements for vasodilation and mild stimulant effects. WADA banned it in competition. The plasma half-life is extremely short, on the order of 6 to 18 minutes, which limits how long any effect lasts. The actual clinical evidence in humans is sparse and the supplement industry uses are mostly extrapolated from beta-agonist class effects. Botanical beta-adrenergic reference compound. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

26/100

Weak botanical beta-2 agonist outcompeted by synthetics on every relevant research dimension

Look, higenamine has enough pharmacology to take seriously as a compound. It’s a benzylisoquinoline alkaloid with genuine beta-2 adrenergic agonist activity, WADA bans it in competition, and the TCM tradition around Aconitum and Nelumbo nucifera isn’t nothing. But real pharmacology isn’t the same as an interesting research target, and on the dimensions we actually care about, higenamine doesn’t clear the bar.

The mechanism story is familiar to the point of being boring. Beta-2 adrenergic agonism is one of the best-characterized receptor biology stories in all of pharmacology. Clenbuterol, albuterol, salmeterol, formoterol: the synthetic beta-2 agonist space is extraordinarily well-trodden. Higenamine adds secondary beta-1 and trace beta-3 activity, but at substantially lower potency than the synthetic tools and with a plasma half-life sitting somewhere between 0.1 and 0.3 hours. That kinetic profile is a real problem for bench work. You can barely establish a steady-state exposure before you’re already measuring decay.

On differentiation, higenamine loses to its synthetic counterparts on almost every axis. If you want to probe beta-2 receptor biology, isoproterenol and clenbuterol are more potent, better characterized, and carry vastly more supporting literature. If you want a botanical probe for ethnopharmacology or alkaloid chemistry, the compound is interesting as one alkaloid in a complex botanical matrix, but thats a narrow use case that doesn’t justify prioritizing it as a primary research object. The idea that natural origin confers special research value over synthetic alternatives has limited support once you examine the pharmacokinetics honestly.

The evidence base reflects its supplement-industry trajectory more than rigorous science. Case reports of cardiovascular adverse events, a handful of pharmacokinetic characterization studies, and receptor-binding data constitute most of the serious literature. The WADA ban confirms real physiological activity, but banning something in sport isn’t a substitute for a replicated mechanistic evidence base. There are no multi-lab mechanistic studies, no phase 2 data, no serious signal that this compound does something synthetic alternatives or the underlying botanical pharmacology doesn’t address better.

We think higenamine has narrow value as a reference probe for investigators specifically interested in the adrenergic pharmacology of benzylisoquinoline alkaloids, and not much beyond that. The half-life is a liability, the potency is modest, and the literature is thin enough that almost any other direction in beta-adrenergic research would be more productive. It’s not junk. But it’s not a priority, and a bench scientist looking for a worthwhile allocation of time should pass.

Novelty: 25
Mechanism promise: 22
In-category differentiation: 20
Evidence quality: 27
Translational signal: 32
Research bench value: 35

Rationale Higenamine scores low on novelty and differentiation because beta-2 adrenergic agonism is an extremely saturated mechanism space, and higenamine is outperformed on potency, half-life, and literature depth by synthetic alternatives. Bench value is minimal outside narrow alkaloid pharmacology niches.

Beta-2 adrenergic agonist (botanical)

A benzylisoquinoline alkaloid found in lotus and aconite; a beta-2 adrenergic agonist used in pre-workout supplements.

Abstract

Higenamine ((R/S)-1-(4-hydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol; CAS 5843-65-2; molecular formula C16H17NO3; molecular weight 271.31) is a benzylisoquinoline alkaloid found in Aconitum, Tinospora cordifolia, Nelumbo nucifera (lotus), and other plants. The compound is a beta-2-preferring adrenergic agonist with secondary beta-1 and limited beta-3 activity; the agonist profile is qualitatively similar to clenbuterol with substantially lower potency. Used in traditional Chinese medicine for cardiac and respiratory indications. Marketed as a pre-workout supplement ingredient for vasodilation and mild stimulant effects. WADA-banned in competition. Plasma half-life is approximately 0.1 to 0.3 hours, very short. Used as a botanical beta-adrenergic agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-384Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Beta-2 adrenergic agonist (botanical)

Higenamine

Abstract

Read the full monograph